Brokers Offer Predictions for Merck & Co.’s Q3 2016 Earnings (MRK)
Merck & Co. (NYSE:MRK) – Leerink Swann boosted their Q3 2016 earnings per share (EPS) estimates for Merck & Co. in a report released on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will earn $0.97 per share for the quarter, up from their previous forecast of $0.96. Leerink Swann currently has a “Hold” rating and a $58.00 price objective on the stock. Leerink Swann also issued estimates for Merck & Co.’s FY2018 earnings at $4.34 EPS and FY2019 earnings at $4.84 EPS.
Merck & Co. (NYSE:MRK) last posted its earnings results on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The firm had revenue of $9.84 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the firm posted $0.86 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis.
MRK has been the topic of a number of other research reports. Berenberg Bank reiterated a “hold” rating and issued a $62.00 price objective on shares of Merck & Co. in a research note on Sunday, September 11th. Argus reiterated a “buy” rating and issued a $65.00 price objective on shares of Merck & Co. in a research note on Wednesday, September 14th. Jefferies Group reiterated a “hold” rating and issued a $56.00 price objective (down previously from $57.00) on shares of Merck & Co. in a research note on Monday, September 12th. Credit Suisse Group AG upgraded shares of Merck & Co. from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $62.00 to $73.00 in a research note on Sunday, August 7th. Finally, Barclays PLC increased their price objective on shares of Merck & Co. from $66.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, September 9th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. Merck & Co. has an average rating of “Hold” and a consensus target price of €63.20 ($70.23).
Merck & Co. (NYSE:MRK) traded down 0.61% during mid-day trading on Friday, hitting $62.28. 4,375,498 shares of the stock were exchanged. The stock has a market cap of $172.22 billion, a PE ratio of 34.16 and a beta of 0.68. Merck & Co. has a 52-week low of $47.97 and a 52-week high of $64.00. The stock’s 50 day moving average is $62.69 and its 200 day moving average is $58.33.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be given a dividend of $0.46 per share. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a yield of 2.94%. Merck & Co.’s payout ratio is presently 101.10%.
In other Merck & Co. news, EVP Adam H. Schechter sold 39,200 shares of the firm’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total transaction of €2,454,312.00 ($2,727,013.33). Following the completion of the sale, the executive vice president now directly owns 39,200 shares in the company, valued at approximately €2,454,312 ($2,727,013.33). The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Clark Golestani sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
A number of large investors have recently made changes to their positions in MRK. First Mercantile Trust Co. raised its stake in shares of Merck & Co. by 4.7% in the third quarter. First Mercantile Trust Co. now owns 86,136 shares of the company’s stock worth $5,369,000 after buying an additional 3,876 shares during the last quarter. R.H. Dinel Investment Counsel Inc. acquired a new stake in shares of Merck & Co. during the third quarter worth approximately $1,166,000. First American Bank raised its stake in shares of Merck & Co. by 11.4% in the third quarter. First American Bank now owns 100,291 shares of the company’s stock worth $6,259,000 after buying an additional 10,284 shares during the last quarter. Independence Advisors LLC raised its stake in shares of Merck & Co. by 3.5% in the third quarter. Independence Advisors LLC now owns 13,262 shares of the company’s stock worth $828,000 after buying an additional 444 shares during the last quarter. Finally, Liberty Capital Management Inc. raised its stake in shares of Merck & Co. by 40.1% in the third quarter. Liberty Capital Management Inc. now owns 6,460 shares of the company’s stock worth $403,000 after buying an additional 1,850 shares during the last quarter. Hedge funds and other institutional investors own 72.93% of the company’s stock.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Stock Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related stocks with our FREE daily email newsletter.